Literature DB >> 10839448

Cost-effective antimicrobial drug selection for the management and control of respiratory disease in European cattle.

D C Barrett1.   

Abstract

Respiratory disease in growing cattle has both animal welfare and economic implications, but the use of antimicrobial drugs to treat and control it is under public scrutiny owing to concerns that their use in food-producing animals may be detrimental to human health. This paper outlines criteria for the selection of appropriate and cost-effective drugs, based on good dinical practice and sound economic principles. It also suggests that these principles should be integrated into quality assurance schemes, and that the monitoring of antimicrobial resistance patterns among known bacterial respiratory pathogens should be improved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839448     DOI: 10.1136/vr.146.19.545

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  4 in total

1.  Determination of the duration of antibacterial efficacy following administration of gamithromycin using a bovine Mannheimia haemolytica challenge model.

Authors:  A B Forbes; C Ramage; J Sales; D Baggott; W Donachie
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Clinical presentation, auscultation recordings, ultrasonographic findings and treatment response of 12 adult cattle with chronic suppurative pneumonia: case study.

Authors:  Philip R Scott
Journal:  Ir Vet J       Date:  2013-04-01       Impact factor: 2.146

3.  The use of MALDI-TOF mass spectrometry for rapid identification of Mannheimia haemolytica.

Authors:  Andrzej Puchalski; Renata Urban-Chmiel; Marta Dec; Diana Stęgierska; Andrzej Wernicki
Journal:  J Vet Med Sci       Date:  2016-04-24       Impact factor: 1.267

4.  T- and B-cell Response Analysis Following Calf Immunisation with Experimental Mycoplasma Bovis Vaccine Containing Saponin and Lysozyme Dimer.

Authors:  Katarzyna Dudek; Dariusz Bednarek
Journal:  J Vet Res       Date:  2017-12-27       Impact factor: 1.744

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.